This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jean-Claude Delarue, PhD; Marie-Francoise Avril, MD; Paule Charpentier, MD; Michel Prade, MD
Institut Gustave-Roussy 39 rue Camille Desmoulins 94800 Villejuif, France

Arch Dermatol. 1987;123(2):159-160.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In the October 1985 issue of the ARCHIVES, Ellis et al¹ stated that estrogen binding is seen in melanomas and melanoma precursor lesions.

In a previous study of 45 cases of malignant melanomas, we concluded that estrogen receptors (ERs) were present in three (7%) of 45 cases of melanomas. If present, their concentration was found to be at the limit of sensitivity of our method. In the literature, the results reported are rather contradictory, since positivity percentages vary from 12%³ to 46%,^4,5 concentrations being in general comparatively low. Some authors⁶ report that estradiolspecific receptors are not involved, the binding being artifactual instead.

Recently, using a histochemical technique with a fluorescent-labeled estrogen compound, Ellis et al¹ showed an important cellular fixation of this compound in several cases of melanoma. These techniques, widely used during the past few years in order to expose the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?